Gyre Therapeutics, Inc. Increase (Decrease) in Receivables
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Receivables of -$123.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2015-07-31
- Gyre Therapeutics, Inc. increase (decrease) in receivables for the quarter ending 2015-06-30 was -$55.00K.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for the quarter ending 2015-03-31 was -$68.00K, a 206.25% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for the quarter ending 2014-12-31 was $89.00K, a 7.29% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for the quarter ending 2014-09-30 was $31.00K, a 96.74% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for fiscal 2014 was -$131.00K.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for fiscal 2013 was -$226.00K, a 119.45% decline from fiscal 2012.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for fiscal 2012 was $1.16M.
- Gyre Therapeutics, Inc. increase (decrease) in receivables for fiscal 2011 was -$620.00K.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month |
|---|---|---|---|---|
| 2015-06-30 | -$55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$123.00K 10-Q · filed 2015-07-31 | -$34.00K derived: sum of 3 quarters · filed 2015-07-31 | -$3.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2015-03-31 | -$68.00K 10-Q · filed 2015-05-07 | $21.00K derived: sum of 2 quarters · filed 2015-05-07 | $52.00K derived: sum of 3 quarters · filed 2015-05-07 | -$263.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $120.00K derived: sum of 2 quarters · filed 2015-03-16 | -$195.00K derived: sum of 3 quarters · filed 2015-07-31 | -$131.00K 10-K · filed 2015-03-16 |
| 2014-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$284.00K derived: sum of 2 quarters · filed 2015-07-31 | -$220.00K 10-Q · filed 2014-11-06 | -$124.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-06-30 | -$315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$251.00K 10-Q · filed 2015-07-31 | -$155.00K derived: sum of 3 quarters · filed 2015-07-31 | $795.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-03-31 | $64.00K 10-Q · filed 2015-05-07 | $160.00K derived: sum of 2 quarters · filed 2015-05-07 | $1.11M derived: sum of 3 quarters · filed 2015-05-07 | |
| 2013-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $1.05M derived: sum of 2 quarters · filed 2015-03-16 | -$226.00K 10-K · filed 2015-03-16 | |
| 2013-09-30 | $950.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$322.00K 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | -$1.27M 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $1.16M 10-K · filed 2015-03-16 | |||
| 2011-12-31 | -$620.00K 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |